1513883-55-0
1513883-55-0
Chemical Structure
Ruxolitinib-d9
Synonym(s): INCB18424-d9
- CAS No.: 1513883-55-0
- Formula:C17H9D9N6
- Molecular Weight:315.42
InChIKey: HFNKQEVNSGCOJV-QNOCMRJCSA-N
SMILES: N#CC[C@H](C1([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C1([2H])[2H])N2C=C(C=N2)C3=C4C(NC=C4)=NC=N3
Biological Activity: Ruxolitinib-d9 (INCB18424-d9) is deuterium labeled Ruxolitinib. Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3[1]. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy[3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ruxolitinib-d9 | Ruxolitinib-d9 (INCB18424-d9) is deuterium labeled Ruxolitinib. Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ruxolitinib (Standard) | 99.74% | Ruxolitinib (Standard) is the analytical standard of Ruxolitinib. This product is intended for research and analytical applications. Ruxolitinib (INCB18424) is a potent and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deuruxolitinib | 99.18% | Deuruxolitinib (CTP-543; Ruxolitinib-d8) is a deuterated analog of Ruxolitinib (HY-50856) and an orally active, selective inhibitor of JAK1 and JAK2. Deuruxolitinib blocks Janus kinase-mediated cytokine receptor signaling and proinflammatory cytokine gene expression. Deuruxolitinib is primarily metabolized in the liver via CYP2C9. Deuruxolitinib promotes scalp hair regrowth in severe chronic alopecia areata. Deuruxolitinib is used in alopecia areata-related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ruxolitinib | 99.95% | Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [3]. Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117. [Content Brief]
